Newswire (Published: Tuesday, June 6, 2017, Received: Friday, June 2, 2017, 3:08:45 AM CDT)

Word Count: 491

Data on Prostate Cancer Reported by Researchers at New York University (Role of MRI prebiopsy in men at risk for prostate cancer: taking off the blindfold)

By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "We review recent literature surrounding the use of prebiopsy prostate MRI and MRI-targeted biopsy in men at risk for prostate cancer. Large series have strengthened the case for the use of MRI prior to prostate biopsy to maximize the detection of clinically significant disease, reduce the detection of clinically insignificant disease, and allow for tumor localization during targeted biopsy."

The news correspondents obtained a quote from the research from New York University, "Prebiopsy MRI followed by targeted biopsy appears to have the ability to overcome the limitations of the standard 12-core template. Use of MRI and targeted biopsy in the setting of a prior negative biopsy is supported by the literature and a recent consensus statement by the American Urological Association and the Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel but is contingent upon the availability and quality of multiparametric MRI acquisition and interpretation. In men with no previous biopsy, MRI and targeted biopsy appears to increase detection of clinically significant disease compared with systematic biopsy while reducing detection of indolent disease. The addition of prostate cancer biomarkers and predictive nomograms may further enhance prebiopsy risk assessment. Prostate MRI prior to biopsy may guide counseling regarding prostate cancer risk, allow for accurate tumor localization during targeted biopsy, and increase detection of clinically significant cancer while limiting detection of indolent disease."

According to the news reporters, the research concluded: "Its use prior to biopsy, in conjunction with biomarkers and predictive nomograms, may allow deferral of biopsy in select cases."

For more information on this research see: Role of MRI prebiopsy in men at risk for prostate cancer: taking off the blindfold. Current Opinion in Urology, 2017;27(3):246-253. Current Opinion in Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion in Urology - journals.lww.com/co-urology/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting S.S. Taneja, New York University, Dept. of Urol, Langone Med Center, Div Urol Oncol, New York, NY 10003, United States. Additional authors for this research include A.B. Rosenkrantz and M.A. Bjurlin (see also Oncology - Prostate Cancer).

Keywords for this news article include: New York City, New York, United States, North and Central America, Cancer Risk, Article Review, Diagnostics and Screening, Metastatic Prostate Cancer, Risk and Prevention, Prostatic Neoplasms, Oncology, New York University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

New York University
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

Central America
North America
United States
Americas
New York
Pennsylvania
New York City
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Radiology
            Urology